Advances in the pharmacological function of FBPase and development of FBPase inhibitors
10.16438/j.0513-4870.2018-0282
- VernacularTitle:果糖-1,6-二磷酸酶及其抑制剂的研究进展
- Author:
Rong-cui LI
1
;
Shuai-nan LIU
1
;
Zhu-fang SHEN
1
Author Information
1. Diabetes Research Center of Chinese Academy of Medical Sciences, Key Laboratory of Polymorphic Drugs of Beijing, State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
- Publication Type:REVIEWS
- Keywords:
fructose-1,6-bisphosptase;
type 2 diabetes mellitus;
gluconeogenesis;
insulin secretion
- From:
Acta Pharmaceutica Sinica
2018;53(9):1477-1483
- CountryChina
- Language:Chinese
-
Abstract:
Fructose 1, 6-bisphosptase (FBPase), a second rate-limiting enzyme in gluconeogenesis, has an important role in the control of gluconeogenesis, which involves in energy metabolism and glucose homeostasis. Inhibitors of FBPase exhibit an anti-diabetic activity. Some of FBPase inhibitors have entered the stage of clinical trials, which indicates that FBPase is a promising therapeutic target for the discovery and development of hypoglycemic drugs. In addition, recent studies have shown that FBPase can be used to treat other diseases such as the initiation and development of tumors in several cancer types. Here, we provide a review of the biological characteristics of FBPase and contributions of FBPase on gluconeogenesis and insulin secretion, the research and development of FBPase inhibitors and the regulatory role of FBPase in other diseases.
